# Scribe Therapeutics (SCTX) — News

SCTX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/sctx/news

## Recent headlines

- [Trex Bio sets IPO target at 8.33M shares](https://www.ainvest.com/news/trex-bio-sets-ipo-target-8-33m-shares-2610) — AInvest Wire, Oct 5, 2026
  Trex Bio has set an IPO target of 8.33 million shares, according to recent filings. The offering is part of a broader trend in the 2026 IPO market, which has already exceeded expectations set earlier in the year. Goldman Sachs had projected $160 billion in US IPO proceeds for 2026, but current data…
- [Scribe Therapeutics - Q2 2026 collaboration revenue $1.90 mln vs $4.90 mln in Q2 2025](https://www.ainvest.com/news/scribe-therapeutics-q2-2026-collaboration-revenue-1-90-mln-4-90-mln-q2-2025-2609) — AInvest Wire, Sep 2, 2026
- [Scribe Therapeutics Inc.: H.C. Wainwright initiates coverage with buy rating and target price $60](https://www.ainvest.com/news/scribe-therapeutics-wainwright-initiates-coverage-buy-rating-target-price-60-2608) — AInvest Wire, Aug 31, 2026
- [Scribe Therapeutics Inc: Leerink Partners initiates coverage with outperform rating; price target $37](https://www.ainvest.com/news/scribe-therapeutics-leerink-partners-initiates-coverage-outperform-rating-price-target-37-2608) — AInvest Wire, Aug 18, 2026
  Leerink Partners has initiated coverage of Scribe Therapeutics Inc. (Nasdaq: SCTX) with an "outperform" rating and a price target of $37 per share. The firm's decision follows the company's successful initial public offering (IPO), which closed on July 27, 2026, with the issuance of 9,867,000…
- [Scribe Therapeutics upsized IPO prices at $15/shr](https://www.ainvest.com/news/scribe-therapeutics-upsized-ipo-prices-15-shr-2607) — AInvest Wire, Jul 24, 2026
  Scribe Therapeutics has priced its initial public offering (IPO) at $15 per share, above the initial $13–$15 range, raising $107.25 million from the sale of 7.15 million shares. The company also has a $10.5 million overallotment option, which, if exercised, would bring total proceeds to…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).